Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064073 | 0.89 | VNN1 (0.47) | ALDH1A1SMN1; SMN2VNN1KCNA5KCNH2 | |
| SCHEMBL884855 | 0.81 | KCNA5 (0.60) | SMN1; SMN2VNN1TDP1KCNA5KCNH2 | |
| SCHEMBL884756 | 0.71 | KCNA5 (0.56) | ALDH1A1VNN1KCNA5KCNH2NPC1 | |
| SCHEMBL2063289 | 0.70 | KCNA5 (0.63) | ALDH1A1SMN1; SMN2KCNA5KCNH2 | |
| SCHEMBL885091 | 0.69 | LMNA (0.62) | ALDH1A1SMN1; SMN2KCNA5KCNH2NPC1 | |
| SCHEMBL2063329 | 0.67 | KCNA5 (0.67) | ALDH1A1SMN1; SMN2KCNA5KCNH2NPC1 | |
| SCHEMBL2063710 | 0.67 | KCNA5 (0.67) | ALDH1A1SMN1; SMN2KCNA5KCNH2NPC1 | |
| SCHEMBL2063815 | 0.67 | KCNA5 (0.66) | ALDH1A1SMN1; SMN2KCNA5KCNH2NPC1 | |
| SCHEMBL885578 | 0.65 | KCNA5 (0.59) | ALDH1A1SMN1; SMN2KCNA5KCNH2RAB9A | |
| SCHEMBL884651 | 0.65 | KCNA5 (0.64) | KCNA5KCNH2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148535-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | ALDH1A1 2989/4885SMN1; SMN2 4477/4885VNN1 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.